#United States #New York #Class Action #Pomerantz Law Firm #INOVIO Pharmaceuticals

Class Action Lawsuit Filed Against Inovio Pharmaceuticals

Overview

On March 12, 2026, Pomerantz LLP announced the initiation of a class action lawsuit against Inovio Pharmaceuticals, Inc., a biotechnology company known for its work in DNA medicines aimed at combating diseases such as HPV. The legal action, filed in the Eastern District of Pennsylvania, includes claims against the company and several of its executives, alleging violations of federal securities laws.

The lawsuit centers around the transactions involving Inovio's securities between October 10, 2023, and December 26, 2025. Investors who purchased securities during this time frame are eligible to join the action by applying to be appointed as Lead Plaintiff until April 7, 2026.

The Allegations

The plaintiffs allege that Inovio's management misled investors regarding the company’s prospects, particularly concerning the regulatory approval process for its flagship product, INO-3107, which targets recurrent respiratory papillomatosis (RRP). Throughout the class period, the defendants were portrayed as optimistic about their potential to gain accelerated approval from the FDA for their Biologics License Application (BLA), only to later disclose manufacturing issues that would significantly delay these plans.

Key Claims

1. Misrepresentation of Product Readiness: Defendants allegedly overstated the readiness of the CELLECTRA device crucial for INO-3107’s efficacy, leading investors to believe the FDA submission was imminent when, in reality, significant production deficiencies remained.
2. Delayed Submission Timeline: Initially touted for mid-2024, the submission was pushed back to mid-2025 due to manufacturing setbacks made known to investors only after the shares had been sold off, leading to considerable losses.
3. False Financial Assurance: Throughout the class period, numerous securities offerings were made, generating millions for the company while denying shareholders the truthful state of product development and market readiness.

The Fallout

These revelations unfolded in a series of press releases and market responses, beginning with Inovio’s announcement on August 8, 2024, where the company stated publicly that it would not be able to submit the BLA until the following year due to manufacturing complications. This news resulted in a decline of 3.1% in Inovio's stock price the following day.

On December 29, 2025, the situation worsened when Inovio further revealed that the FDA had accepted their BLA but would proceed with a standard review, failing to qualify for any expedited processes as earlier indicated by the company. Investor confidence plummeted, reflected in a 24.45% drop in shares, closing at $1.73.

About Pomerantz LLP

Pomerantz LLP, with a rich legacy in investor protection, has established itself as a leader in class action litigation, recovering significant damages on behalf of shareholders over its 85-year history. The firm advocates for those affected by securities fraud, breach of fiduciary duty, and corporate misconduct, guiding investors through claiming their rightful dues. With offices across major cities and a commitment to holding corporations accountable, Pomerantz remains active in litigating cases that empower shareholders.

Conclusion

As the situation continues to evolve, the Inovio case underscores the importance of transparency and truthful communication in the biotechnology sector, especially given the potential impact on investor trust and market stability. Those interested in joining the class action or seeking further information can visit Pomerantz's official site or reach out directly through provided contact details.